China is encouraging new drug development, including a commercial insurance catalog for innovative medicines, allowing patient reimbursement. This catalog will feature highly innovative drugs and those with significant clinical value, not covered by basic medical insurance, and is recommended for commercial insurance adoption.
While China's basic medical insurance covers a vast population, its funding is limited. The new catalog aims to clarify coverage, foster commercial plan growth, and combine funds from basic and commercial insurance.
The commercial health insurance industry is growing. The administration will develop the list, respecting commercial insurers' market status, with industry experts involved. Companies can apply for both basic and commercial lists simultaneously.
Drug innovation is a priority. Since 2018, many innovative drugs have been added to the basic reimbursement list. To support international expansion, confidential pricing negotiations will be implemented for companies, especially those in the commercial catalog.
5 Comments
Bermudez
Patients should never have to worry about which plan covers their medication. This is a fundamental right, not a privilege.
Africa
Sounds like a scheme to make money off the vulnerable. Basic medical insurance should cover all necessary medications.
Mariposa
This approach seems more focused on incentivizing drug manufacturers than on improving public health.
Muchacha
This is just more corporate greed in the healthcare system. Innovation should not come with a price tag!
Bella Ciao
How can we trust the government's decisions when they prioritize commercial interests over public health?